
Opinion|Videos|July 29, 2024
Biosimilars in the Commercial Sector
Dr. Cannon discusses payers and PBMs making decisions about biosimilars in the commercial sector.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How are payers and PBMs making decisions about biosimilars in the commercial sector?
a. What key factors are considered for formulary decisions in the commercial sector?
b. Discussion points: What makes the commercial sector unique, employer/payer payment models.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Medicaid Work Requirements Mirror Programs in Georgia, Arkansas: Ciara Zachary, PhD, MPH
2
FDA Approves Sevabertinib for Nonsquamous NSCLC
3
Herbal Use Linked to Lower Autoantibodies in Dermatomyositis
4
How Effective and Safe Are GLP-1s for Weight Loss?
5














































